Small Caps to Watch | Freedom Broker Names Four Small Caps With Up to 40% Upside: Which Stocks Stand Out?
TAT Technologies Ltd. TATT | 0.00 | |
Intrepid Potash, Inc. IPI | 0.00 | |
Sarepta Therapeutics, Inc. SRPT | 0.00 | |
Piedmont Realty Trust Inc Class A PDM | 0.00 | |
Russell 2000 ETF IWM | 0.00 |
While mega-cap technology stocks continue to dominate investor attention, several small-cap names are attracting interest on improving financial results, changing supply-demand dynamics, and company-specific catalysts.
In its latest biweekly report, Freedom Broker highlighted four small-cap stocks across aerospace, biotechnology, fertilizers, and commercial real estate, with potential upside of up to around 40% based on the share prices at the time of the report.
From a fundamental perspective, TAT Technologies Ltd.(TATT.US) and Intrepid Potash, Inc.(IPI.US) have the clearest improvement in operating performance. Sarepta Therapeutics, Inc.(SRPT.US) is more dependent on catalysts, while Piedmont Realty Trust Inc Class A(PDM.US) represents a bet on a recovery in the office property market.
Four Stocks, Four Investment Stories
| Stock | Key thesis | Main catalyst | Key risks |
|---|---|---|---|
| TAT Technologies Ltd.(TATT.US) | Aerospace growth and strong backlog | Revenue and order growth | Valuation and supply chains |
| Intrepid Potash, Inc.(IPI.US) | Potash scarcity and improving earnings | Prices, production and buybacks | Commodity cycle |
| Piedmont Realty Trust Inc Class A(PDM.US) | Office-property recovery | Rents, occupancy and FFO | Rates and debt |
| Sarepta Therapeutics, Inc.(SRPT.US) | Gene-therapy sales recovery | ELEVIDYS and new data | FDA, clinical trials and sales |
1. TAT Technologies: Record Backlog Supports Growth
Ticker: TAT Technologies Ltd.(TATT.US)
TAT Technologies provides components, maintenance, repair and overhaul services for the commercial and military aerospace sectors. Freedom Broker set a $54 price target, representing around 40% upside when the report was issued.
The company's second-quarter results showed continued improvement, with revenue reaching $52.9 million, up 22.8% year over year, while net income rose to $8.1 million. Its backlog and long-term agreements also reached a record $615 million at the end of June, providing strong visibility into future revenue.
The company is also benefiting from easing supply-chain constraints and expanding cooperation with Honeywell Aerospace.
Technical view
The stock has recently moved lower to $36, meaning the upside to the $54 target is now bigger than the 40% potential cited in the original report.
Bottom line: TAT Technologies Ltd.(TATT.US) is primarily a growth story backed by strong orders and improving earnings, but after the recent rally, continued earnings growth matters more than simply chasing the target price.
2. Sarepta Therapeutics: ELEVIDYS Recovery Comes With High Risk
Ticker: Sarepta Therapeutics, Inc.(SRPT.US)
Freedom Broker set a $25 price target, implying around 27% upside when its report was released.
Sarepta reported $328.7 million in net product revenue for the second quarter, including $98.1 million from its ELEVIDYS gene therapy. However, total revenue fell 34% year over year to $401.3 million, primarily because of lower ELEVIDYS sales following changes to the treatment's label.
The investment thesis therefore depends heavily on a recovery in ELEVIDYS sales and the progress of the company's newer gene-therapy programs. Sarepta also expects important data readouts from its DM1 and FSHD programs.
Technical view
Sarepta Therapeutics, Inc.(SRPT.US) was around $19.22 on Aug. 21, up roughly 9% over the previous week and 13% over the previous month, while its beta stood at 2.29, highlighting its high volatility.
Bottom line: Sarepta Therapeutics, Inc.(SRPT.US) offers some of the highest potential upside and volatility among the four stocks, but it is also the most dependent on regulatory, clinical and product-sales catalysts.
3. Intrepid Potash: A Bet on Potash Supply Constraints and Improving Earnings
Ticker: Intrepid Potash, Inc.(IPI.US)
Intrepid Potash is the only U.S. producer of potash, a key factor behind Freedom Broker's positive view.
The company's operating performance has also been improving. In the second quarter, gross profit increased to $16.6 million, from $12.4 million a year earlier, while adjusted EBITDA rose to $17.5 million. The company also raised its production outlook and reduced its capital expenditure guidance to around $40 million.
The sale of an asset for approximately $68.9 million also strengthened liquidity, while the company expanded its share-repurchase authorization to $50 million.
Technical view
The stock has recently traded in roughly the $38 - $40 range. Short-term indicators remain somewhat weak, while the monthly signal has turned bullish.
Freedom Broker's $45 price target still represents meaningful upside from recent levels.
Bottom line: Intrepid Potash, Inc.(IPI.US) combines improving operating performance with structural support from limited domestic potash supply, although the stock remains exposed to the commodity cycle.
4. Piedmont Realty Trust: Is the Office Market Approaching a Turning Point?
Ticker: Piedmont Realty Trust Inc Class A(PDM.US)
Piedmont Realty Trust specializes in Class A office properties in the U.S. Sun Belt. Freedom Broker set a $11 price target for the stock.
In the second quarter, the company signed leases covering around 460,000 square feet, with cash rents rising more than 14% and same-store cash net operating income increasing 9%.
The company also raised its 2026 Core FFO guidance to $1.50-$1.55 per share, pointing to continued improvement in operating performance.
Technical view
Piedmont Realty Trust Inc Class A(PDM.US) was recently around $9.73, up approximately 20% over the past 3 months and 25% over the past year. Freedom Broker has also noted that the stock had gained more than 50% from its March low, reducing its attractiveness compared with earlier levels.
Bottom line: Piedmont Realty Trust Inc Class A(PDM.US) is a bet on a recovery in office real estate, higher rents and improving occupancy, but part of that recovery already appears to be reflected in the share price.
Key Takeaways: Investors focused on earnings visibility may find TATT and IPI the clearest stories. PDM depends on continued improvement in the office-property market, while SRPT offers the greatest potential volatility and event-driven upside, alongside the highest level of risk.
For small-cap stocks, price targets should not be treated as guarantees. Liquidity, sector cycles and company-specific events can all drive sharp moves away from fundamentals.
Note: Price targets reflect Freedom Broker's views at the time of its reports. Financial figures are based on the latest available company disclosures, while market and technical data are sourced from platforms such as TradingView where available. Prices and technical indicators change with market conditions. This content is not investment advice.